GSK reacts to FDA's new guidelines for asthma drugs

With the FDA's newest recommendations for labeling asthma drugs, specifically those known as long-acting beta-agonists.

GSK responded:
“We will work with FDA to ensure that the final label for these products protects the interest of patients who suffer with this chronic and serious disease. It is important that doctors have flexibility to make the proper clinical decisions to help patients gain and maintain optimal control of their asthma.”

Read more about the response here.

Share this article with your social network, just click below to share now!

Share |